Cargando…

Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study

BACKGROUND: Protease inhibitor monotherapy is associated with more frequent episodes of viral rebounds above 50 copies/mL than triple therapy. Objective: To evaluate if, compared to triple-drug therapy, protease inhibitor monotherapy is associated with increased levels of inflammatory/procoagulant m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Estébanez, Miriam, Stella-Ascariz, Natalia, Mingorance, Jesús, Pérez-Valero, Ignacio, Bernardino, Jose Ignacio, Zamora, Francisco Xavier, Montes, Maria Luisa, González-García, Juan Julián, Arribas, José Ramón
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4097047/ https://www.ncbi.nlm.nih.gov/pubmed/25015544 http://dx.doi.org/10.1186/1471-2334-14-379

Ejemplares similares

Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy
por: Pérez-Valero, Ignacio, et al.
Publicado: (2013)

Long-Term Control of Human Immunodeficiency Virus-1 Replication Despite Extensive Resistance to Current Antiretroviral Regimens: Clonal Analysis of Resistance Mutations in Proviral Deoxyribonucleic Acid
por: Stella-Ascariz, Natalia, et al.
Publicado: (2016)

Cerebral volumes, neuronal integrity and brain inflammation measured by MRI in patients receiving PI monotherapy or triple therapy
por: Pérez Valero, Ignacio, et al.
Publicado: (2014)

Facial emotional processing deficits in long-term HIV-suppressed patients
por: Gonzalez-Baeza, Alicia, et al.
Publicado: (2014)

Residual Viremia in Treated HIV(+) Individuals
por: Conway, Jessica M., et al.
Publicado: (2016)

Naïve patients receiving TDF/FTC-EFV as 2 pills are more likely to modify regimen components than patients receiving a TDF/FTC/EFV single pill
por: Perez-Valero, I, et al.
Publicado: (2010)

Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials
por: Arribas, Jose, et al.
Publicado: (2014)

Residual Viremia Is Preceding Viral Blips and Persistent Low-Level Viremia in Treated HIV-1 Patients
por: Hofstra, Laura Marije, et al.
Publicado: (2014)

Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting
por: Arribas, José R, et al.
Publicado: (2013)

Low-level residual viremia and risk of virological failure
por: Cologni, G, et al.
Publicado: (2010)

Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment
por: Aamer, Hadega A., et al.
Publicado: (2020)

Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis
por: Mathis, Sandra, et al.
Publicado: (2011)

Reduced adherence to antiretroviral therapy is associated with residual low-level viremia
por: Maggiolo, Franco, et al.
Publicado: (2017)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

The Magic of Proteases: From a Procoagulant and Anticoagulant Factor V to an Equitable Treatment of Its Inherited Deficiency
por: De Pablo-Moreno, Juan A., et al.
Publicado: (2023)

Incidence of post-transplant cytomegalovirus viremia in patients receiving lungs after ex vivo lung perfusion
por: Ribeiro, Rafaela V.P., et al.
Publicado: (2023)

Systemic inflammation and residual viraemia in HIV-positive adults on protease inhibitor monotherapy: a cross-sectional study
por: Arenas-Pinto, Alejandro, et al.
Publicado: (2015)

Clinical significance of procoagulant microparticles
por: Nomura, Shosaku, et al.
Publicado: (2015)

A contradictory action of procoagulant ficin by a fibrinolytic serine protease from Egyptian Ficus carica latex
por: Hamed, Mohamed B., et al.
Publicado: (2020)

Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral Therapy
por: Bakkour, Sonia, et al.
Publicado: (2020)

Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patients
por: Oddershede, Lars, et al.
Publicado: (2014)

Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance
por: De Miguel Buckley, Rosa, et al.
Publicado: (2022)

Differential Effects of Viremia and Microbial Translocation on Immune Activation in HIV-Infected Patients Throughout Ritonavir-Boosted Darunavir Monotherapy
por: BenMarzouk-Hidalgo, Omar J., et al.
Publicado: (2015)

Bocavirus viremia
por: Sukkaromdee, Pathoom, et al.
Publicado: (2015)

Procoagulant inhibitory properties of paclitaxel poliglumex
por: Nemunaitis, John, et al.
Publicado: (2010)

Procoagulant and Anticoagulant Factors in Childhood Hypothyroidism
por: Kilic, Nevin, et al.
Publicado: (2012)

Impact of Epicatechin on the Procoagulant Activities of Microparticles
por: Sinegre, Thomas, et al.
Publicado: (2020)

Evaluation Procoagulant Activity and Mechanism of Astragalin
por: Li, Changqin, et al.
Publicado: (2020)

The state of PI monotherapy and NRTI-sparing therapy
por: Arribas, JR
Publicado: (2010)

The MONET trial: correlation between Hepatitis C coinfection and HIV RNA responses during darunavir/ritonavir monotherapy, for patients with HIV RNA <50 copies/mL at baseline
por: Arribas, Jose R, et al.
Publicado: (2010)

No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial
por: Li, Jonathan Z, et al.
Publicado: (2019)

The kinetics of SARS-CoV-2 viremia in COVID-19 patients receiving remdesivir
por: Krifors, Anders, et al.
Publicado: (2023)

Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy
por: Dunn, David T., et al.
Publicado: (2018)

No Differences of Immune Activation and Microbial Translocation Among HIV-infected Children Receiving Combined Antiretroviral Therapy or Protease Inhibitor Monotherapy
por: Falcon-Neyra, Lola, et al.
Publicado: (2015)

High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial
por: Pasquau, Juan, et al.
Publicado: (2018)

The Procoagulant Snake Venom Serine Protease Potentially Having a Dual, Blood Coagulation Factor V and X-Activating Activity
por: Latinović, Zorica, et al.
Publicado: (2020)

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens
por: López-Cortés, Luis F., et al.
Publicado: (2016)

The procoagulant effects of fine particulate matter in vivo
por: Kilinç, Evren, et al.
Publicado: (2011)

Procoagulant activity and thrombelastography in Korean hemorrhagic fever.
por: Lee, M., et al.
Publicado: (1986)

Polyphosphate and omptins: novel bacterial procoagulant agents
por: Yun, Thomas H, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_sp45bibteutl0avh88m3vascj5